An independent, board-ready assessment designed for pre-commercial and early-revenue medical device companies considering an early acquisition.
Why Most Early MedTech Exits Fail
Most early-stage medtech exits fail not because the technology lacks merit, but because timing, signalling, and credibility gaps go unaddressed until it’s too late.
● Buyers stop returning calls● Key value signals never materialize● Regulatory or clinical assumptions don’t hold● Capital constraints quietly close exit windows
Download the Board & Investor Brief (PDF)A 2-page summary designed for internal board or investor discussion
Compare with the Early Exit Roadmap
Outcomes
Clear go / conditional / no-go verdict
Realistic buyer categories
Priority actions (if applicable)
Explicit recommendation on next steps
Pricing & Duration
A cost and time efficient service that provides the information you need to determine next steps.
Should that next step include planning or executing a medical device M&A exit, your entire fee can be credited toward our Early Exit Roadmap service.
Need to circulate this internally? Download the Board & Investor Brief (PDF)
No hourly charges, monthly retainers or longterm commitments. Just the critical information you need, in a timely manner, for one flat fee.
$3750
2–3 weeks duration
100% credit toward any level of our Early Exit Roadmap service if engaged within 60 days of Early Assessment Completion
All fees payable in USD, Credit Cards Accepted
Used by Boards and Investors for Portfolio Decision-Making
The Early Exit Assessment is often commissioned by lead investors or boards to evaluate strategic options, capital efficiency, and exit viability across early-stage medical device portfolios.
It provides an independent, buyer-informed perspective to support hold, advance, or exit decisions.
Your Questions, Answered
Frequently Asked Questions
What qualifies as an 'early exit' and how do you evaluate whether one is viable?
An early exit is generally understood as an asset or equity divestment transaction that occurs prior to the company/technology fulfilling its commercial promise. In medical device M&A early exits that's often pre-revenue and sometimes, pre-clinical/regulatory clearance. We determine the viability of an exit initiative by assessing the technology, market trends, competitors, prospective buyer activity, and general valuation expectations.
How long will it take and what factors impact that?
Our standard duration is 2-3 weeks to deliver our final report. The speed at which we can deliver is highly dependent on the speed at which you give us the critical information about your company and technology that we need to conduct our research.
Who should consider an early exit? Is it possible if we are pre-commercial?
Yes, it's entirely possible to pursue a successful early exit at the pre-commercial stage in medical device M&A. The primary factors that determine whether an early exit is feasible are: strong IP, desirable technology that fills an acknowledged gap, prospective buyer alignment, and good timing. You should consider an early exit if you've hit a critical development milestone, have seen strong M&A activity in your medical device sector, are nearing the commercialization stage, or conversely, are nearing the end of your funding runway and cannot finance further development.
I'm interested in the Early Exit Roadmap service; is this service a pre-requisite?
No, the Early Exit Assessment isn't a pre-requisite to accessing our Early Exit Roadmap service. If you're confident that a medical device M&A early exit is your best option, you may wish to move straight to the Early Exit Roadmap service. If you're weighing your options and need an unbiased, research based assessment regarding the feasibility and best timing of a successful exit, the Early Exit Assessment is a strong choice and, as noted, you can apply 100% of the Assessment fee to any of the Early Exit Roadmap levels afterward, should you choose to go that route.
Can I credit the fee toward any level of the Early Exit Roadmap service?
Yes, absolutely. You can choose from three levels of Roadmap to prepare for your medtech early exit and 100% of your Assessment fee will be applied to the level you choose, as long as you book your Roadmap engagement within 60 days of the conclusion of your Assessment service.
If it's determined that a medical device M&A early exit is viable, can we engage you to lead it?
Deal leads are time intensive so my availability is somewhat limited and dependent on the stage and complexity of my current engagements. Happily, many exit initiatives can be led by founders or corporate executives successfully with our Roadmap service and, if required, additional advisory support once the initiative is underway. We can discuss your preference and my availability prior to, or during, your Assessment or Roadmap service.